Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl.

INCLUSION CRITERIA: PAH and PH-IPF * WHO Functional Class (or equivalent classification) II - IV. * Subjects using supplemental oxygen must be receiving a stable course of therapy for a minimum of 14 days prior to study drug administration. * All subjects' oxygen saturation must be \> or = to 88% at time of treatment * Echocardiogram within 6 months of baseline showing no signs of clinically significant left sided heart disease * Females of child-bearing potential with a negative urine pregnancy test, or a documented surgical sterilization, or is post-menopausal prior to administration of investigational product. Females of childbearing potential must be practicing adequate birth control. PAH (WHO Group 1) ONLY-Inclusion * Documented diagnosis of WHO Group 1 PAH, (limited to, idiopathic, heritable, drug and toxin induced, associated with connective tissue disease, portal hypertension, repaired congenital heart disease, HIV); documented by a previous RHC and hemodynamics consistent with PAH, WHO Group 1 * Pulmonary Function Testing within 6 months prior to screening/enrollment shows no evidence of interstitial lung disease (TLC\<70%) or obstructive lung disease (FEV1/FVC ratio \<50%) * Receiving a stable course of approved PAH oral mono therapies for a minimum of 14 days prior to treatment period * Must be 18-80 year of age PH-IPF (WHO Group 3) ONLY-Inclusion * Documented diagnosis of probable or definite IPF using ATS/ERS criteria * Previous transbronchial biopsy, if pe…